Decoy Therapeutics Inc.: 10-Q filed 2019-11-12

Name: Decoy Therapeutics Inc.: 10-Q filed 2019-11-12
Creator: Decoy Therapeutics Inc.

What Decoy Therapeutics Inc. reported in its quarterly report filed 2019-11-12 (fiscal Q3 2019): 32 published measures, 87 facts as tagged in accession 0001615219-19-000054.

This filing

Form: 10-Q (quarterly report)
Filed: 2019-11-12
Fiscal period: fiscal Q3 2019
Accession: 0001615219-19-000054 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Decoy Therapeutics Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2019-09-30	14,457,946	USD
At 2018-12-31	6,613,823	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit	Days
At 2019-09-30	4,720,913	USD
At 2018-12-31	7,884,937	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit
At 2019-09-30	9,737,033	USD
At 2019-06-30	732,913	USD
At 2019-03-31	1,730,282	USD
At 2018-12-31	-1,271,114	USD
At 2018-09-30	-1,488,157	USD
At 2018-06-30	-1,184,140	USD
At 2018-03-31	-3,315,871	USD
At 2017-12-31	-2,900,426	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit	Days
At 2019-09-30	3,999,676	USD
At 2018-12-31	3,228,288	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2019-07-01 to 2019-09-30	-2,627,721	USD	92
2019-01-01 to 2019-09-30	-5,053,442	USD	273
2019-04-01 to 2019-06-30	-903,645	USD	91
2019-01-01 to 2019-03-31	-1,522,076	USD	90
2018-07-01 to 2018-09-30	-307,450	USD	92
2018-01-01 to 2018-09-30	-577,766	USD	273
2018-04-01 to 2018-06-30	111,233	USD	91
2018-01-01 to 2018-03-31	-381,549	USD	90

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2019-01-01 to 2019-09-30	-8,943,538	USD	273
2018-01-01 to 2018-09-30	3,789,651	USD	273

Contract revenue excluding tax

Revenue from customer contracts excluding assessed taxes under this specific taxonomy concept. It is not automatically comparable to older revenue tags.

Period	Value	Unit	Days
2019-07-01 to 2019-09-30	874,949	USD	92
2019-01-01 to 2019-09-30	2,426,362	USD	273
2018-07-01 to 2018-09-30	469,051	USD	92
2018-01-01 to 2018-09-30	1,312,752	USD	273

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2019-01-01 to 2019-09-30	1,203,525	USD	273
2018-01-01 to 2018-09-30	1,741,310	USD	273

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

Period	Value	Unit	Days
2019-01-01 to 2019-09-30	5,607,908	USD	273
2018-01-01 to 2018-09-30	0	USD	273

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2019-09-30	-10,193,879	USD
At 2018-12-31	-5,140,437	USD

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

Period	Value	Unit	Days
At 2019-09-30	28,144	USD
At 2018-12-31	37,525	USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

Period	Value	Unit	Days
2019-01-01 to 2019-09-30	579,721	USD	273
2018-01-01 to 2018-09-30	52,781	USD	273

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2019-07-01 to 2019-09-30	-3,760,165	USD	92
2019-01-01 to 2019-09-30	-6,205,051	USD	273
2018-07-01 to 2018-09-30	-313,514	USD	92
2018-01-01 to 2018-09-30	-584,690	USD	273

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2019-09-30	5,239,384	USD
At 2018-12-31	6,380,867	USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

Period	Value	Unit	Days
At 2019-09-30	1,643,083	USD
At 2018-12-31	373,834	USD

Goodwill carrying amount

Recognized goodwill remaining after accumulated impairment. It arises from business combinations and does not measure the current value of the company’s brand.

Period	Value	Unit	Days
At 2019-09-30	8,865,909	USD
At 2018-12-31	0	USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

Period	Value	Unit	Days
2019-07-01 to 2019-09-30	4,635,114	USD	92
2019-01-01 to 2019-09-30	8,631,413	USD	273
2018-07-01 to 2018-09-30	782,565	USD	92
2018-01-01 to 2018-09-30	1,897,442	USD	273

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2019-07-01 to 2019-09-30	1,140,909	USD	92
2019-01-01 to 2019-09-30	2,680,982	USD	273
2018-07-01 to 2018-09-30	353,607	USD	92
2018-01-01 to 2018-09-30	803,846	USD	273

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2019-09-30	3,756,184	shares
At 2018-12-31	2,032,763	shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

Period	Value	Unit
At 2019-09-30	3,999,676	USD
At 2018-12-31	6,131,781	USD
At 2018-09-30	6,050,298	USD
At 2017-12-31	519,337	USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

Period	Value	Unit	Days
At 2019-09-30	19,927,156	USD
At 2018-12-31	3,867,290	USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

Period	Value	Unit	Days
At 2019-09-30	324,509	USD
At 2018-12-31	195,431	USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

Period	Value	Unit	Days
At 2019-09-30	1,239,708	USD
At 2018-12-31	249,086	USD

Current contract liabilities

Consideration received before performance obligations are satisfied, often called deferred revenue. It is an obligation to deliver, not earned revenue or cash available.

Period	Value	Unit	Days
At 2019-09-30	1,580,394	USD
At 2018-12-31	4,006,755	USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2019-07-01 to 2019-09-30	3,494,205	USD	92
2019-01-01 to 2019-09-30	5,950,431	USD	273
2018-07-01 to 2018-09-30	428,958	USD	92
2018-01-01 to 2018-09-30	1,093,596	USD	273

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

Period	Value	Unit	Days
2019-01-01 to 2019-09-30	123,174	USD	273
2018-01-01 to 2018-09-30	12,713	USD	273

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

Period	Value	Unit	Days
2019-01-01 to 2019-09-30	6,867	USD	273
2018-01-01 to 2018-09-30	0	USD	273

Income taxes paid, net

Cash income taxes paid net of refunds during the period. It differs from income tax expense and can reflect prior years and estimated payments.

Period	Value	Unit	Days
2019-01-01 to 2019-09-30	0	USD	273
2018-01-01 to 2018-09-30	0	USD	273

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

Period	Value	Unit	Days
2018-01-01 to 2018-12-31	2,869,412	USD	365

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

Period	Value	Unit	Days
2019-01-01 to 2019-09-30	-690	USD	273
2018-01-01 to 2018-09-30	0	USD	273

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

Period	Value	Unit	Days
2019-01-01 to 2019-09-30	-1,169	USD	273
2018-01-01 to 2018-09-30	0	USD	273

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

Period	Value	Unit	Days
2019-01-01 to 2019-09-30	-593,351	USD	273
2018-01-01 to 2018-09-30	-452,102	USD	273

Inspect the source

Entity: Decoy Therapeutics Inc. / CIK 0001615219
Captured: 2026-09-21T17:20:32.388Z
SEC response SHA-256: 3dae29679ef228e32bff301a79640d7e283fcc5b87c08a4882faedfce1c66e98

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001615219.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))